Novel Antihypertensive Agents Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2

Angiotensin-converting enzyme 2 (ACE2) is a key renin-angiotensin system enzyme involved in balancing the adverse effects of angiotensin II on the cardiovascular system, and its overexpression by gene transfer is beneficial in cardiovascular disease. Therefore, our objectives were 2-fold: to identify compounds that enhance ACE2 activity using a novel conformation-based rational drug discovery strategy and to evaluate whether such compounds reverse hypertension-induced pathophysiologies. We used a unique virtual screening approach. In vitro assays revealed 2 compounds (a xanthenone and resorcinolnaphthalein) that enhanced ACE2 activity in a dose-dependent manner. Acute in vivo administration of the xanthenone resulted in a dose-dependent transient and robust decrease in blood pressure (at 10 mg/kg, spontaneously hypertensive rats decreased 71 9 mm Hg and Wistar-Kyoto rats decreased 21 8 mm Hg; P 0.05). Chronic infusion of the xanthenone (120 g/day) resulted in a modest decrease in the spontaneously hypertensive rat blood pressure (17 mm Hg; 2-way ANOVA; P 0.05), whereas it had no effect in Wistar-Kyoto rats. Strikingly, the decrease in blood pressure was also associated with improvements in cardiac function and reversal of myocardial, perivascular, and renal fibrosis in the spontaneously hypertensive rats. We conclude that structure-based screening can help identify compounds that activate ACE2, decrease blood pressure, and reverse tissue remodeling. Administration of ACE2 activators may be a valid strategy for antihypertensive therapy. (Hypertension. 2008; 51:1312-1317.)

[1]  A. Ferreira,et al.  Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. , 2007, Life sciences.

[2]  M. Raizada,et al.  ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. , 2006, Physiological genomics.

[3]  G. Díaz-Araya,et al.  Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted Rat , 2006, Hypertension.

[4]  Merlin C. Thomas,et al.  Developmental expression of ACE2 in the SHR kidney: a role in hypertension? , 2006, Kidney international.

[5]  Jie Liang,et al.  CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues , 2006, Nucleic Acids Res..

[6]  J. Grobe,et al.  Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. , 2006, American journal of physiology. Heart and circulatory physiology.

[7]  N. Alenina,et al.  Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice , 2006, Hypertension.

[8]  L. Kay,et al.  Intrinsic dynamics of an enzyme underlies catalysis , 2005, Nature.

[9]  M. Huentelman,et al.  Protection from angiotensin II‐induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats , 2005, Experimental physiology.

[10]  D. Diz,et al.  Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.

[11]  Georgia Hadjipavlou,et al.  Linkage between dynamics and catalysis in a thermophilic-mesophilic enzyme pair , 2004, Nature Structural &Molecular Biology.

[12]  D. Averill,et al.  Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors , 2004, Hypertension.

[13]  Li Xing,et al.  Evaluation and application of multiple scoring functions for a virtual screening experiment , 2004, J. Comput. Aided Mol. Des..

[14]  Saurabh Menon,et al.  ACE2 X-Ray Structures Reveal a Large Hinge-bending Motion Important for Inhibitor Binding and Catalysis , 2004, Journal of Biological Chemistry.

[15]  Q. Lin,et al.  Increased Angiotensin-(1-7)–Forming Activity in Failing Human Heart Ventricles: Evidence for Upregulation of the Angiotensin-Converting Enzyme Homologue ACE2 , 2003, Circulation.

[16]  M. Crackower,et al.  Angiotensin-converting enzyme 2 is an essential regulator of heart function , 2002, Nature.

[17]  H. Berman,et al.  Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank , 2022 .

[18]  T. Parsons,et al.  Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase* , 2002, The Journal of Biological Chemistry.

[19]  J. Egido,et al.  Angiotensin II and renal fibrosis. , 2001, Hypertension.

[20]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[21]  Nigel M. Hooper,et al.  A Human Homolog of Angiotensin-converting Enzyme , 2000, The Journal of Biological Chemistry.

[22]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[23]  C. Ferrario,et al.  Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. , 1996, Hypertension.

[24]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[25]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[26]  E. Eisenmesser,et al.  Enzyme dynamics during catalysis measured by NMR spectroscopy. , 2005, Methods in enzymology.

[27]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.